<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242827</url>
  </required_header>
  <id_info>
    <org_study_id>C0701/2025/ON/US</org_study_id>
    <nct_id>NCT00242827</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma</brief_title>
  <official_title>An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <brief_summary>
    <textblock>
      An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients
      with Advanced Multiple Myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients
      with Advanced Multiple Myeloma.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2006</start_date>
  <completion_date>May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral CEP-701</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are included in the study if all of the following criteria are met:

          -  Histological and cytological confirmation of stage II or III multiple myeloma.

          -  Relapsed or primary refractory multiple myeloma, after 1 or more courses of standard
             therapy, and progressive disease.

          -  ECOG performance status of 0-1.

          -  Measurable disease as defined by serum M protein of more than 1.0 gm/dl, serum light
             chain of more than 200 mg/dL, or Bence-Jones proteinuria of more than 200mg/24 hours.

          -  At least 18 years of age.

          -  Normal marrow function: ANC&gt;1.0x10 9/L, platelets&gt;50X10 9/L An exception is allowed if
             myelosuppression or thrombocytopenia is secondary to bone marrow plasmacytosis. Growth
             factor support is allowed.

          -  Normal organ function: bilirubin &lt;1.5XULN, AST and ALT&lt;2XULN, serum creatinine &lt;2.0
             mg/dL.

          -  Contraceptive measures during participation as appropriate.

          -  Willing to be able to comply with study procedures and restrictions.

          -  Signed written informed consent.

        Exclusion Criteria:

        Patients are excluded from participating in this study if 1 or more of the following
        criteria are met:

          -  Nonsecretory disease or plasma cell leukemia (defined as &gt;2000 circulating plasma
             cells/uL).

          -  More than 4 prior courses if anticancer therapy (bisphosphonates are not considered
             anticancer therapy for this criterion)

          -  Chemotherapy or radiotherapy within 4 weeks prior to enrollment

          -  Unresolved adverse events or uncontrolled illness that would be likely to interfere
             with the objectives of the study.

          -  Treatment with an investigational drug within 4 weeks of first day of study treatment

          -  History of second cancer (except for adequately treated basal cell or squamous cell
             skin cancer, in situ cervical cancer, or other cancer for which the patient has been
             disease free more than 5 years).

          -  Treatment with potent CYP3A4 inhibitors including cyclosporine, clotrimazole,
             fluconazole, itraconazole, ketoconazole, voriconazole, erythromycin, clarithromycin,
             and troleandomycin, human immunodeficiency virus (HIV), protease inhibitors, or
             nefazodone within 1 week (7 days) of the planned 1st day of study treatment.

          -  Currently receiving warfarin.

          -  Clinical diagnosis of active gastrointestinal ulceration of melena or hematemesis in
             the previous 4 weeks.

          -  Hypersensitivity to CEP701 or any component of CEP701.

          -  Intolerance of dexamethasone.

          -  Requirement for HIV protease inhibitor treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Brown</last_name>
    <role>Study Director</role>
    <affiliation>Cephalon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univeristy Cancer Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Center Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center Of University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>October 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2005</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

